- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2049-3002
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin ; volume:9 ; number:1 ; day:11 ; month:12 ; year:2021 ; pages:1-18 ; date:12.2021
Cancer & metabolism ; 9, Heft 1 (11.12.2021), 1-18, 12.2021
- Creator
-
Šimčíková, Daniela
Gardáš, Dominik
Hložková, Kateřina
Hruda, Martin
Žáček, Petr
Rob, Lukáš
Heneberg, Petr
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40170-021-00277-2
- URN
-
urn:nbn:de:101:1-2022021819200143106066
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Šimčíková, Daniela
- Gardáš, Dominik
- Hložková, Kateřina
- Hruda, Martin
- Žáček, Petr
- Rob, Lukáš
- Heneberg, Petr
- SpringerLink (Online service)
Other Objects (12)
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade
Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade
Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers
Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade